Gene targeting strategy for B-hCSF1/CSF1R mice. The exon 2-8 of mouse Csf1 gene that encodes the full-length protein were replaced by human CSF1 exon 2-8 in B-hCSF1/CSF1R mice. The exon 3-11 of mouse Csf1r gene that encode the extracellular protein were replaced by human CSF1R exon 3-11 in B-hCSF1/CSF1R mice.

Strain specific CSF1 expression analysis in homozygous B-hCSF1/hCSF1R mice by ELISA. Splenocytes were collected from wild-type C57BL/6 mice (+/+) and homozygous B-hCSF1/hCSF1R mice (H/H) stimulated with LPS in vivo, and analyzed by ELISA with species-specific anti-CSF1 ELISA kit. Mouse CSF1 was detectable in wild-type mice. Human CSF1 was exclusively detectable in homozygous B-hCSF1/hCSF1R but not in wild-type mice. ND: Not detected.

Strain specific CSF1R expression analysis in homozygous B-hCSF1/hCSF1R mice by flow cytometry. Blood were collected from wild-type C57BL/6 mice (+/+) and homozygous B-hCSF1/hCSF1R mice (H/H), and analyzed by flow cytometry with species-specific anti-CSF1R antibody. Mouse CSF1R was detectable in wild-type mice. Human CSF1R was exclusively detectable in homozygous B-hCSF1/hCSF1R but not in wild-type mice.

Antitumor activity of anti-mouse PD-L1 antibody combined with anti-human CSF1R antibody in B-hCSF1/hCSF1R mice. (A) Anti-mouse PD-L1 antibody combined with anti-human CSF1R antibody inhibited hCSF1-MC38 tumor growth in B-hCSF1/hCSF1R mice. Murine colon cancer hCSF1-MC38 cells (5Χ10⁵) (hCSF1-MC38 cells provided by a client) were subcutaneously implanted into homozygous B-hCSF1/hCSF1R mice (female, n=5). Mice were grouped on the first day, at which time they were treated with anti-mouse PD-L1 antibody (provided by a client) and anti-human CSF1R antibody (provided by a client) with doses and schedules indicated in panel A. (B) Body weight changes during treatment. As shown in panel A, anti-human CSF1R antibody and combination of anti-mouse PD-L1 antibody and anti-human CSF1R antibody were efficacious in controlling tumor growth in B-hCSF1/hCSF1R mice, demonstrating that the B-hCSF1/hCSF1R mice provide a powerful model for in vivo evaluation of anti-human CSF1R antibodies and their combination with PD-L1 antibodies. Values are expressed as mean ± SEM.
Note: This experiment was performed by the client using B-hCSF1/hCSF1R mice. All the other materials were provided by the client.

Antitumor activity of anti-human CSF1R antibodies in B-hCSF1/hCSF1R mice. (A) Anti-human CSF1R antibodies inhibited MC38 tumor growth in B-hCSF1/hCSF1R mice. Murine colon cancer MC38 cells were subcutaneously implanted into homozygous B-hCSF1/hCSF1R mice (female, 6-7-week-old, n=6). Mice were grouped when tumor volume reached approximately 100 mm³, at which time they were treated with two anti-human CSF1R antibodies with doses and schedules indicated in panel. (B) Body weight changes during treatment. (C) Mouse survival after grouping. As shown in panel A and C, anti-human CSF1R antibodies were efficacious in controlling tumor growth in B-hCSF1/hCSF1R mice, demonstrating that the B-hCSF1/hCSF1R mice provide a powerful preclinical model for in vivo evaluation of anti-human CSF1R antibodies. Values are expressed as mean ± SEM.